Literature DB >> 24771535

Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Imke Metz1, Stephen D Weigand, Bogdan F G Popescu, Josa M Frischer, Joseph E Parisi, Yong Guo, Hans Lassmann, Wolfgang Brück, Claudia F Lucchinetti.   

Abstract

OBJECTIVE: Multiple sclerosis (MS) lesions demonstrate immunopathological heterogeneity in patterns of demyelination. Previous cross-sectional studies reported immunopatterns of demyelination were identical among multiple active demyelinating lesions from the same individual, but differed between individuals, leading to the hypothesis of intraindividual pathological homogeneity and interindividual heterogeneity. Other groups suggested a time-dependent heterogeneity of lesions. The objective of our present study was to analyze tissue samples collected longitudinally to determine whether patterns of demyelination persist over time within a given patient.
METHODS: Archival tissue samples derived from patients with pathologically confirmed central nervous system inflammatory demyelinating disease who had undergone either diagnostic serial biopsy or biopsy followed by autopsy were analyzed immunohistochemically. The inclusion criteria consisted of the presence of early active demyelinating lesions--required for immunopattern classification--obtained from the same patient at 2 or more time points.
RESULTS: Among 1,321 surgical biopsies consistent with MS, 22 cases met the study inclusion criteria. Twenty-one patients (95%) showed a persistence of immunopathological patterns in tissue sampled from different time points. This persistence was demonstrated for all major patterns of demyelination. A single patient showed features suggestive of both pattern II and pattern III on biopsy, but only pattern II among all active lesions examined at autopsy.
INTERPRETATION: These findings continue to support the concept of patient-dependent immunopathological heterogeneity in early MS and suggest that the mechanisms and targets of tissue injury may differ among patient subgroups. These observations have potentially significant implications for individualized therapeutic approaches.
© 2014 American Neurological Association.

Entities:  

Mesh:

Year:  2014        PMID: 24771535      PMCID: PMC4070313          DOI: 10.1002/ana.24163

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  34 in total

1.  Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease.

Authors:  S J Pittock; R L McClelland; S J Achenbach; F Konig; A Bitsch; W Brück; H Lassmann; J E Parisi; B W Scheithauer; M Rodriguez; B G Weinshenker; C F Lucchinetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

2.  Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

Authors:  Mark Keegan; Fatima König; Robyn McClelland; Wolfgang Brück; Yazmín Morales; Andreas Bitsch; Hillel Panitch; Hans Lassmann; Brian Weinshenker; Moses Rodriguez; Joseph Parisi; Claudia F Lucchinetti
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

3.  Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.

Authors:  Franziska Di Pauli; Simone Mader; Kevin Rostasy; Kathrin Schanda; Barbara Bajer-Kornek; Rainer Ehling; Florian Deisenhammer; Markus Reindl; Thomas Berger
Journal:  Clin Immunol       Date:  2010-12-18       Impact factor: 3.969

4.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

5.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.

Authors:  Kevin C O'Connor; Katherine A McLaughlin; Philip L De Jager; Tanuja Chitnis; Estelle Bettelli; Chenqi Xu; William H Robinson; Sunil V Cherry; Amit Bar-Or; Brenda Banwell; Hikoaki Fukaura; Toshiyuki Fukazawa; Silvia Tenembaum; Susan J Wong; Norma P Tavakoli; Zhannat Idrissova; Vissia Viglietta; Kevin Rostasy; Daniela Pohl; Russell C Dale; Mark Freedman; Lawrence Steinman; Guy J Buckle; Vijay K Kuchroo; David A Hafler; Kai W Wucherpfennig
Journal:  Nat Med       Date:  2007-01-12       Impact factor: 53.440

6.  Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis.

Authors:  Nathan P Young; Brian G Weinshenker; Joseph E Parisi; B Scheithauer; C Giannini; Shanu F Roemer; Kristine M Thomsen; Jayawant N Mandrekar; Bradley J Erickson; Claudia F Lucchinetti
Journal:  Brain       Date:  2010-02-03       Impact factor: 13.501

Review 7.  Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

Authors:  Orhan Aktas; Bernd Kieseier; Hans-Peter Hartung
Journal:  Trends Neurosci       Date:  2010-01-04       Impact factor: 13.837

8.  Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis.

Authors:  Francisco J Quintana; Mauricio F Farez; Vissia Viglietta; Antonio H Iglesias; Yifat Merbl; Guillermo Izquierdo; Miguel Lucas; Alexandre S Basso; Samia J Khoury; Claudia F Lucchinetti; Irun R Cohen; Howard L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-21       Impact factor: 11.205

9.  Persistence of immunopathological and radiological traits in multiple sclerosis.

Authors:  Fatima B König; Brigitte Wildemann; Stefan Nessler; Dun Zhou; Bernhard Hemmer; Imke Metz; Hans-Peter Hartung; Bernd C Kieseier; Wolfgang Brück
Journal:  Arch Neurol       Date:  2008-11

10.  Mitochondrial defects in acute multiple sclerosis lesions.

Authors:  Don Mahad; Iryna Ziabreva; Hans Lassmann; Douglas Turnbull
Journal:  Brain       Date:  2008-05-30       Impact factor: 13.501

View more
  52 in total

1.  Glutamate Transporters: Expression and Function in Oligodendrocytes.

Authors:  Edna Suárez-Pozos; Elizabeth J Thomason; Babette Fuss
Journal:  Neurochem Res       Date:  2019-01-09       Impact factor: 3.996

2.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

Review 3.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

Review 4.  Multiple sclerosis outcomes after cancer immunotherapy.

Authors:  Catherine R Garcia; Rani Jayswal; Val Adams; Lowell B Anthony; John L Villano
Journal:  Clin Transl Oncol       Date:  2019-02-20       Impact factor: 3.405

5.  Preferential Recruitment of Neutrophils into the Cerebellum and Brainstem Contributes to the Atypical Experimental Autoimmune Encephalomyelitis Phenotype.

Authors:  Yudong Liu; Andrew T Holdbrooks; Gordon P Meares; Jessica A Buckley; Etty N Benveniste; Hongwei Qin
Journal:  J Immunol       Date:  2015-06-17       Impact factor: 5.422

6.  Multimodal partial volume correction: Application to [11C]PIB PET/MRI myelin imaging in multiple sclerosis.

Authors:  Elisabetta Grecchi; Mattia Veronese; Benedetta Bodini; Daniel García-Lorenzo; Marco Battaglini; Bruno Stankoff; Federico E Turkheimer
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

7.  Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.

Authors:  Stephanie A Harmon; Michael J Tuite; Robert Jeraj
Journal:  Phys Med Biol       Date:  2016-10-03       Impact factor: 3.609

Review 8.  Advanced MRI and staging of multiple sclerosis lesions.

Authors:  Martina Absinta; Pascal Sati; Daniel S Reich
Journal:  Nat Rev Neurol       Date:  2016-04-29       Impact factor: 42.937

9.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.

Authors:  Josa M Frischer; Stephen D Weigand; Yong Guo; Nilufer Kale; Joseph E Parisi; Istvan Pirko; Jay Mandrekar; Stephan Bramow; Imke Metz; Wolfgang Brück; Hans Lassmann; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2015-08-24       Impact factor: 10.422

Review 10.  Spring cleaning: time to rethink imaging research lines in MS?

Authors:  Martina Absinta; Daniel S Reich; Massimo Filippi
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.